Novartis study shows need for chronic urticaria therapy improvements

Novartis has announced new findings from a real-world study that demonstrate failings in the current approach to treating chronic urticaria.

The assessment analysed data from 3,733 chronic urticaria patients involved in the worldwide non-interventional AWARE study, which aims to characterise the impact of the disease across 12 European countries.

It was shown that 42 percent of patients are not receiving any treatment at all for the condition, despite 83 percent experiencing a negative impact on their quality of life as a result.

Indeed, more than half of patients reported the effect of chronic urticaria on their quality of life as moderate, very large or extremely large, with many individuals still experiencing problems despite receiving treatment.

Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said: "These findings reinforce the urgent need to improve the management of chronic urticaria in line with treatment guidelines, calling for a treatment goal of a 'symptom-free patient'."

Chronic urticaria is a severe disease that causes itchy, persistent hives and painful swelling that can last for years or decades. Novartis markets a drug called Xolair as a treatment for this condition.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.